AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

A-17 Archaeal Proteasome to Digest Human Aggregating Proteins

Technology Benefits
ΓùÅ Simple: Archaeal proteasome only has one pair of ╬▒, ╬▓ subunits while human has 7 different ╬▒, ╬▓ subunitsΓùÅ Higher activity: Archaeal proteasome has much higher activity in digesting polyglutamine chains compared to human proteasomesΓùÅ Specific: This proteasome digests only aggregating proteins related to neuronal disorders
Technology Application
ΓùÅ Therapeutic Medicine for Neuronal Disorders (ParkinsonΓÇÖs, ALS, Polyglutamine, AlzheimerΓÇÖs Diseases)ΓùÅ Preventive MedicineΓùÅ Research Tool
Detailed Technology Description
None
Supplementary Information
Inventor: Ramesh, Narayanaswamy | Anton, Ines M. | Hartwig, John H. | Geha, Raif S.
Priority Number: US6635446B1
IPC Current: C07K001447 | C12N001512
US Class: 4350691 | 4352523 | 4353201 | 435325 | 530395 | 5360235
Assignee Applicant: The Children's Medical Center Corporation,Boston
Title: WIP, a WASP-associated protein
Usefulness: WIP, a WASP-associated protein
Summary: WIP or DNA encoding WIP can be administered to an individual, in sufficient quantity to alter actin content and/or the extent to which polymerization occurs, and thus, to prevent or reduce (totally or partially) cytoskeletal abnormalities and other adverse effects. In particular, Wiskott-Aldrich syndrome can be treated or prevented in this manner.
Industry
Biomedical
Sub Category
Medical Composition
*Abstract
Researchers at Nagoya University have identified that an archaeal proteasome is useful for digesting an aggregating protein such as mutant superoxide dismutase 1 (SOD1) or an androgen receptor (AR) having an abnormally extended polyglutamine chain in human cells. It has been shown that this proteasome only digests aggregating proteins which are related to neuronal disorders. This technology provides an expression construct for digesting an aggregating protein which has a nucleic acid encoding an archaeal proteasome and being connected in an operable manner to a promoter for eukaryotic cells. By transfecting this expression construct into human cells, the aggregating protein is digested owing to the action of the archaeal proteasome.
Country/Region
USA

For more information, please click Here
Mobile Device